GLYCOMIMETICS INC

CBIO

Explore Our Financial Data > Companies > Wilmington, Maryland Companies > GLYCOMIMETICS INC
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
CBIO
CIK0001253689
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Website glycomimetics.com
Phone240-243-1201
CEOHarout Semerjian
Employees50

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$10.84 million
Pre-Tax Income$-151.94 million
Net Income$-153.94 million
Net Income to Common$-153.94 million
EPS$-12.81
View All
Balance Sheet
Cash$213.19 million
Assets$240.29 million
Liabilities$37.28 million
Common Equity$199.01 million
Liabilities & Equity$240.29 million
View All
Cash Flow Statement
Net Income$-153.94 million
Cash From Operating Activities$-71.53 million
Cash From Investing Activities$-72.92 million
Cash From Financing Activities$322.98 million
Change in Cash$178.53 million
View All
Calculations
NOPAT$-106.84 million
EBITDA$-152.55 million
Price to EarningsN/A
Price to Book$2.68
ROE-157.46%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 35,325 shares of the Company’s ordinary shares to three non-executive employees as equity inducement awards under th

Article Link

Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 45,675 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the

Article Link

Crescent Biopharma: Q4 Earnings Snapshot

WALTHAM, Mass. AP) — Crescent Biopharma, Inc. CBIO) on Thursday reported a loss of $92.4 million in its fourth quarter.

Article Link

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors with three additional clinical trials across the portfolio expected to initiate in 2026 Completed $185 million private placement, supporting several key clinical data readouts beginning in Q1 2027 and providing expected cash runway into 2028 WA

Article Link

Crescent Biopharma to Present at March Investor Conferences

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March: TD Cowen 46th Annual Health Care Conference, fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston.Leerink Partners 2026 Global Healthcare Confere

Article Link